Clinical outcomes, bacterial loads, and markers of intestinal inflammation in immunocompromised and cancer patients with diarrhea and Clostridioides difficile identified by nucleic acid amplification tests (NAAT) and toxin A/B by enzyme immunoassay (EIA)